Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma

Lemieux, Bernard; Tartas, Sophie; Traulle, Catherine; Espinouse, Daniel; Thiéblemont, Catherine; Bouafia, Fadhela; Alhusein, Q; Antal, Daciana; Salles, Gilles; Coiffier, Bertrand

doi:10.1038/sj.bmt.1704467

Cited by 88 publications

(43 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, a high incidence of late-onset neutropenia following rituximab-containing chemotherapy and/or autologous stem cell transplantation has been reported, however, its mechanism still remains to be solved. 25,26 Larger studies and longer follow-ups are necessary to confirm these findings and to determine more optimal combinations of rituximab and auto-PBSCT as well as the impact of rituximab on disease-free survival in the treatment of NHL. Effect of rituximab on mobilization and engraftment of PBSC K Kamezaki et al…”

Section: Discussionmentioning

confidence: 99%

Rituximab does not compromise the mobilization and engraftment of autologous peripheral blood stem cells in diffuse-large B-cell lymphoma

Kamezaki

Kikushige

Numata

et al. 2007

Bone Marrow Transplant

View full text Add to dashboard Cite

To investigate effects of the preautografting administration of rituximab on the mobilization and engraftment of peripheral blood stem cells (PBSC), we retrospectively analyzed the outcomes of 43 newly diagnosed diffuse-large B-cell lymphoma patients who received CHOP chemotherapy with or without rituximab as a first-line treatment before autologous PBSC transplantation (PBSCT). There was no difference in the number of CD34 þ cells among PBSC between the non-rituximab and the rituximab groups. Although B-cells were completely depleted from PBSC in the rituximab group, we found no difference in the expression of CXCR-4, VLA-4 and c-Kit on PBSC, indicating that rituximab did not affect the expression of these adhesion molecules, which might be involved in the mechanism of mobilization. There was no significant difference in the recovery of neutrophils and platelets, transplant-related toxicity and post-transplant complications between the two groups. Despite the short follow-up, there was no significant difference in progression-free survival between the two groups. These results indicated no adverse effect of rituximab on the mobilization and engraftment of PBSC. Larger studies are required to determine the impact of rituximab on the mobilization and function of PBSC as well as whether a survival advantage exists in patients who undergo auto-PBSCT with rituximab.

show abstract

Section: Discussionmentioning

confidence: 99%

Rituximab does not compromise the mobilization and engraftment of autologous peripheral blood stem cells in diffuse-large B-cell lymphoma

Kamezaki

Kikushige

Numata

et al. 2007

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…However, such cytopenias have been described with rituximab in lymphoma patients; their mechanisms are not completely understood. 29 Flow cytometry results showed that ofatumumab did result in the rapid and prolonged depletion of circulating normal B lymphocytes in all patients. Serial evaluation demonstrated that recovery to normal levels was not observed until 5 to 6 months after completion of therapy, and in a subset of patients the depletion was sustained until the end of the study period, month 12.…”

Section: Discussionmentioning

confidence: 99%

Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study

Coiffier

Leprêtre²,

Pedersen

et al. 2008

Blood

356

218

View full text Add to dashboard Cite

Safety and efficacy of the fully human anti-CD20 monoclonal antibody, ofatumumab, was analyzed in a multicenter dose-escalating study including 33 patients with relapsed or refractory chronic lymphocytic leukemia. Three cohorts of 3 (A), 3 (B), and 27 (C) patients received 4, once weekly, infusions of ofatumumab at the following doses: (A) one 100 mg and three 500 mg; (B) one 300 mg and three 1000 mg; (C) one 500 mg and three 2000 mg. Sixty-seven percent of the patients were Binet stage B, and the median number of previous treatments was 3. The maximum tolerated dose was not reached. The majority of related adverse events occurred at first infusion, and the number of adverse events decreased at each subsequent infusion. Seventeen (51%) of 33 patients experienced infections, 88% of them of grade 1-2. One event of interstitial pneumonia was fatal; all other cases resolved within one month. The response rate of cohort C was 50% (13/26), one patient having a nodular partial remission and 12 patients partial remission. In conclusion, ofatumumab was found to be well tolerated in patients with chronic lymphocytic leukemia (CLL) in doses up to 2000 mg. Preliminary data on safety and objective response are encouraging and support further studies on the role of ofatumumab in CLL patients. This trial was registered at www.clinicaltrials.gov as no.

show abstract

“…Delayed neutropenia usually occurs in patients treated with rituximab alone or in combination with chemotherapy. It appears between 1 and 6 months after the last infusion, may be transient, rarely associated with infection and resolve spontaneously in most of the cases (Lemieux et al, 2004b). The mechanisms are not fully understood.…”

Section: Safety and Tolerabilitymentioning

confidence: 99%

“…However, this treatment may be associated with more infections (Neumann et al, 2006). It had been associated with severe decrease in immunoglobulin levels (Lim et al, 2005) and more frequent neutropenia (Lemieux et al, 2004b).…”

Section: Mab and High-dose Therapy With Asctmentioning

confidence: 99%

Rituximab therapy in malignant lymphoma

2007

Self Cite

View full text Add to dashboard Cite

Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma

Cited by 88 publications

References 10 publications

Rituximab does not compromise the mobilization and engraftment of autologous peripheral blood stem cells in diffuse-large B-cell lymphoma

Rituximab does not compromise the mobilization and engraftment of autologous peripheral blood stem cells in diffuse-large B-cell lymphoma

Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study

Rituximab therapy in malignant lymphoma

Contact Info

Product

Resources

About